• No menu assigned!
  • Home
    • Home
    • About
    • All Posts
    • Authors
    • FAQs
    • Advertise
    • Contact Us
  • Trending
  • Eat
  • Adventure
  • Parties
  • Art
  • Style
  • Stuff
  • Interest
  • Advocacies
  • Deals

Philippines set to begin Avigan clinical trials on 100 COVID-19 patients

The Department of Health announced this Wednesday that Japan is set...

  • May 7, 2020
  • • 0
  • • 0

Philippine Hospitals to Launch Plasma Therapy for COVID-19 Patients

Positive results from the first trials of Philippine General...

  • Apr 30, 2020
  • • 0
  • • 0

Experimental Drug Remdesivir Reportedly Showing Positive Results for COVID-19 Patients

STAT News reported last April 16 that COVID-19 patients being treated...

  • Apr 23, 2020
  • • 0
  • • 0

PGH Eyes Using Antibodies in Blood of Survivors to Treat COVID-19 Patients

The University of the Philippines (UP) – Philippine General...

  • Apr 5, 2020
  • • 0
  • • 0

DOH Considers a Japanese Anti-Flu Drug as Treatment for COVID-19 Patients

The Philippines’ Department of Health is currently looking into...

  • Mar 31, 2020
  • • 0
  • • 0

WHO’s COVID-19 Treatment Trial Has Found Its First Patients

The World Health Organization (WHO) announced on Friday that the...

  • Mar 29, 2020
  • • 0
  • • 0

Biotech Firm Identifies Antibodies for Treatment of COVID-19

American biotechnology company Regeneron Pharmaceuticals Inc. has...

  • Mar 25, 2020
  • • 0
  • • 0

About When In Manila

WhenInManila.com is a community of writers, photographers, videographers, and storytellers, who share their discoveries and stories about Manila, Philippines, and the world. We are the biggest blog and online magazine in the Philippines, garnering millions of impressions per day throughout our various online media outlets. Connect with us now to get featured or to promote your business, products, or brands! For advertising inquiries, head to www.wheninmanila.com/advertise. Find more info on www.wheninmanila.com/faq

  • Home
  • Authors
  • About
  • Advertise
  • Contact Us
  • FAQs
  • Terms & Conditions